Acapodene
Trademark details
Acapodene® is a registered trademark used for Pharmaceutical Preparations and Compounds For Use In Connection With the Treatment of Precancerous Lesions of the Prostate To Prevent Prostate Cancer and the Prevention and Treatment of Prostate Cancer and Pharmaceutical Preparations For Use In Connection With the Treatment of the Side Effects of Prostate Cancer Therapy and owned by GTx, Inc.. Full trade mark registration details, registered images and more information below.
| Goods and/or Services: | Pharmaceutical Preparations and Compounds For Use In Connection With the Treatment of Precancerous Lesions of the Prostate To Prevent Prostate Cancer and the Prevention and Treatment of Prostate Cancer and Pharmaceutical Preparations For Use In Connection With the Treatment of the Side Effects of Prostate Cancer Therapy |
| Serial Number: | 76548599 |
| Registration Number: | 2926770 |
| Filing Date: | Oct 2, 2003 |
|
Last Applicant(s)/ Owner(s) of Record | GTx, Inc.Three Dunlap Avenue |
| Related Products: | Pharmaceuticals |
Suppliers
Total : 1 View more »
Gtx, Inc. in Memphis, Tennessee, USA
Edit this Company edit this company Gtx, Inc. 3 N Dunlap St Van Vleet B Memphis, Tennessee 38163-0001 USA tel: +1 9015239700 http://www.gtxinc...
Web Sites
powered by 
Total : 23,300 View more »
Prostate: Acapodene for PIN
Welcome to GTx, a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways ...
Flexyx: Acapodene (Generic name - Toremifene) OnLine Information
Acapodene (Generic name - Toremifene) OnLine Information - A first generation selective estrogen receptor modulator (SERM). Like tamoxifen, it is an estrogen agonist ...
Medical News: Toremifene (Acapodene) Reduces Fracture Risk from ...
Explain to patients that an investigational hormonal therapy known as toremifene (Acapodene) has shown potential for reducing the risk of bone fracture in prostate ...
Acapodene Meets Primary And Key Secondary Endpoints In Phase III ...
Ipsen (Paris:IPN) announced that GTx Inc. (NASDAQ: GTXI), from which it licensed the European rights for Acapodene® (toremifene citrate 80 mg) in September 2006 ...
News and Blogs
Total : 4 View more »
GTx Has to Reevaluate Options Following Prostate Cancer Drug Failure -- Seeking Alpha
...Share GTx’s (GTXI) main shot at redemption for its lead pipeline candidate, toremifene (acapodene), failed to deliver with the release Tuesday night of phase III data that showed no significant reduction in the...
October FDA Calendar Stocks: Tricks or Treats? -- Seeking Alpha
...expects to issue a safety update on LibiGel by the end of October. GTx Inc. (NASDAQ: GTXI) has a pending NDA for Acapodene (toremifene) 80 mg with a PDUFA action date of 10/30/09 as part of standard 10-month review...
'Lucky 13 Portfolio': Fuel Systems and Three Cancer Drug Makers -- Seeking Alpha
...14 article on ARIA. (3) GTX Inc. On October 30, regulators are also scheduled to review GTXI's new drug Acapodene® which is indicated for the treatment of bone loss in men with prostate cancer. Disclosure: Long ARIA and SPPI...
FDA Calendar: 2H09 Binary Event Trades -- Seeking Alpha
...GTx Inc. (NASDAQ:GTXI) reported quarterly results and stated that is conducting a pivotal Phase 3 clinical trial evaluating Acapodene (toremifene) 20 mg for the prevention of prostate cancer in men with high-grade pre-cancerous prostate...
Explore Related Topics:
